Scarica l'app Stockscreener
157.57
1.51%
-2.2439
Precedente Chiudi:
$159.81
Aprire:
$159.85
Volume 24 ore:
381.04K
Relative Volume:
0.27
Capitalizzazione di mercato:
$21.52B
Reddito:
$1.53B
Utile/perdita netta:
$-214.69M
Rapporto P/E:
-89.53
EPS:
-1.76
Flusso di cassa netto:
$-43.68M
1 W Prestazione:
+13.94%
1M Prestazione:
-1.89%
6M Prestazione:
-7.81%
1 anno Prestazione:
+32.24%
Intervallo 1D:
$155.27
$161.38
Intervallo di 1 settimana:
$136.21
$165.09
Portata 52W:
$110.57
$183.00
Natera Inc Stock (NTRA) Company Profile
Nome
Natera Inc
Settore
Industria
Telefono
650-249-9090
Indirizzo
13011 MCCALLEN PASS, AUSTIN, CA
Confronta NTRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
157.59 | 21.55B | 1.53B | -214.69M | -43.68M | -1.76 |
|
TMO
Thermo Fisher Scientific Inc
|
485.10 | 174.60B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
208.15 | 143.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
661.89 | 52.17B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
119.70 | 32.42B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
189.64 | 30.62B | 15.50B | 1.33B | 2.16B | 7.34 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-01-23 | Iniziato | Barclays | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-04-08 | Ripresa | Craig Hallum | Buy |
| 2024-02-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2023-12-29 | Reiterato | BTIG Research | Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-11-13 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-09-28 | Iniziato | Bernstein | Mkt Perform |
| 2023-07-05 | Ripresa | JP Morgan | Overweight |
| 2023-05-05 | Iniziato | UBS | Buy |
| 2023-01-18 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-04-25 | Iniziato | Stephens | Overweight |
| 2022-03-08 | Iniziato | Goldman | Buy |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-06-15 | Iniziato | Raymond James | Mkt Perform |
| 2021-05-25 | Iniziato | Wells Fargo | Overweight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-09-28 | Iniziato | Morgan Stanley | Overweight |
| 2020-09-17 | Iniziato | SVB Leerink | Outperform |
| 2020-06-10 | Ripresa | Piper Sandler | Overweight |
| 2020-05-07 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-10-05 | Iniziato | JP Morgan | Neutral |
| 2018-07-05 | Reiterato | Piper Jaffray | Overweight |
| 2017-08-07 | Reiterato | Morgan Stanley | Overweight |
| 2016-11-10 | Reiterato | The Benchmark Company | Buy |
| 2016-05-23 | Reiterato | The Benchmark Company | Buy |
| 2016-05-11 | Reiterato | The Benchmark Company | Buy |
| 2016-04-19 | Iniziato | The Benchmark Company | Buy |
| 2015-09-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2015-08-14 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2015-08-04 | Iniziato | Robert W. Baird | Outperform |
| 2015-07-27 | Iniziato | Morgan Stanley | Equal-Weight |
| 2015-07-27 | Iniziato | Piper Jaffray | Overweight |
| 2015-07-27 | Iniziato | Wedbush | Neutral |
Mostra tutto
Natera Inc Borsa (NTRA) Ultime notizie
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera price target raised to $195 from $185 at Morgan Stanley - TipRanks
Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies - MSN
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Natera's Signatera test to be covered under Medicare - MSN
How much upside does Natera Inc. haveAnalyst Upgrade Watch - thegnnews.com
What is the Moat Score of Natera Inc.Free Growth Stock Screener - mustnews.co.kr
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Call Transcript - Insider Monkey
What technical models suggest about Natera Inc.’s comebackFree Secure Capital Picks With Upside Potential - Newser
14 Best Aggressive Growth Stocks to Buy According to Analysts - Insider Monkey
Natera shares surge 17% after strong Q2 results and upgraded guidance - Invezz
Natera Stock: Growth or Bubble? - StocksToTrade
Natera Inc. Stocks Soar After Impressive Q2 Results - timothysykes.com
Natera’s Stock Leaps Amid Clinical Trial Success - StocksToTrade
Natera (NTRA) Shares Surge on Q2 Outperformance: Is This a Sustainable Growth Story or a Short-Term Overreaction? - AInvest
Natera price target raised to $200 from $194 at Baird - TipRanks
Why Are Natera (NTRA) Shares Soaring Today - Yahoo Finance
Natera Gets First Nod for $8.25 Million Prenatal Test Settlement - Bloomberg Law News
Natera (NTRA) Is Up 5.6% After Raising Revenue Outlook and Launching New Prenatal Test - simplywall.st
Natera’s Latest Achievements Elevate Prospects Post-World Transplant Congress - timothysykes.com
Natera Stock (NTRA) Soars 14% on Strong Financial Results - TipRanks
Natera’s Strong Growth and Strategic Advancements Justify Buy Rating - TipRanks
Natera 2025 Q2 Earnings Deepened Losses Amid Revenue Surge - AInvest
Natera stock price target raised to $255 from $251 at RBC Capital - Investing.com Canada
Bernstein SocGen raises Natera stock price target to $205 on strong revenue - Investing.com
Natera, Inc. shares rise 15.18% premarket after reporting a 32.2% revenue increase in Q2 and raising 2025 outlook. - AInvest
RBC Raises Price Target on Natera to $255 From $251, Keeps Outperform Rating - MarketScreener
Natera price target raised to $200 from $195 at BTIG - TipRanks
Natera's Q2 2025: Unraveling Contradictions in Signatera Growth, Women's Health Impact, and Japanese ASP Aspirations - AInvest
Natera stock price target raised to $215 from $200 at TD Cowen - Investing.com Canada
Earnings call transcript: Natera Q2 2025 sees revenue beat, stock surges - Investing.com UK
Natera's Genetic Gambit: Pioneering the Future of Prenatal Diagnostics Through Innovation and Market Expansion - AInvest
Natera Stock Soars 13.4% on 32.2% Revenue Surge - AInvest
Natera (NASDAQ:NTRA) Delivers Strong Q2 Numbers, Stock Jumps 12.6% - Yahoo Finance
Natera Q2 2025 slides: 32% revenue growth drives raised guidance, stock surges - Investing.com Canada
Natera Inc (NTRA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and Raised Guidance By GuruFocus - Investing.com Canada
Natera Inc Azioni (NTRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Natera Inc Azioni (NTRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sheena Jonathan | CO-FOUNDER |
Aug 11 '25 |
Sale |
153.67 |
3,000 |
461,012 |
34,282 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Aug 01 '25 |
Sale |
132.88 |
5,807 |
771,656 |
163,593 |
| Marcus Gail Boxer | Director |
Aug 01 '25 |
Sale |
133.17 |
2,496 |
332,395 |
5,763 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Aug 01 '25 |
Sale |
132.89 |
3,000 |
398,657 |
123,059 |
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):